



2019

21 - 23 JUNE
SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE

Oncofertility: from now to next

Francesca E. Duncan, PhD
Department of Obstetrics and Gynecology
Northwestern University

MASCC/ISOO

Annual Meeting on Supportive Care in Cancer

www.mascc.org/meeting

Follow us on Twitter: @CancerCareMASCC



#MASCC19



2019

21-23 JUNE
SAN FRANCISCO

**SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE**

I have nothing to disclose



Cancer treatments, while life preserving, can have off-target effects




2019

21-23 JUNE

SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE

Age-related effects of cancer treatments



Cupit-Link CT et al, ESMO Open, 2017

Childhood Cancer Survivor Study – survivors first diagnosed at age 21 and followed up for a median of 24.5 years after diagnosis along with their siblings





Fig 3. Hazard ratios and 95% CIs of survivors versus siblings for specific chronic conditions that first occurred at or after age 35 years, adjusted for age, race, and sex. CHF, congestive heart failure.

Armstrong GT et al, JCO, 2014



Cancer treatments can affect all aspects of the reproductive axis



2019


21-23 JUNE
SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE



Who is at risk?

- More than **1.4 million** people are diagnosed with cancer in the US annually and **10 million** globally
- **10%** of these individuals are in their reproductive years
- **1 in 750** in the US is a childhood cancer survivor
- Survivors are significantly more likely to be **infertile** or have **difficulty getting pregnant** than their siblings
- **Fertility and sexual functioning** are key health related quality of life concerns in young adult survivors of childhood cancer




Jeruss and Woodruff, *NEJM*, 2009
Howlader N, SEER Cancer Statistics Review 1975-2012
Phillips et al, *CEBP*, 2015 NCI Office of Cancer Survivorship
Robison L. & Hudson MM, *Nature Reviews Cancer* 2014
Nightingale et al, *JAYAO*, 2011



The Oncofertility Consortium - a New Paradigm

A global 10+ year NIH-funded interdisciplinary initiative to explore and expand the reproductive future of cancer survivors



2019

21-23 JUNE

SAN FRANCISCO

**SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE**

Duncan *et al*, Reproductive Endocrinology, 8th Edition



Fertility Preservation Options for Men

CLINICAL FERTILITY PRESERVATION OPTIONS

For men, standard methods include:


- 1 TESTIS SHIELDING
- 2 SPERM BANKING
- 3 SPERM EXTRACTION

Experimental method:

- 4 TESTICULAR TISSUE CRYOPRESERVATION

CANCER TREATMENT

- 1 RADIATION
- 2 SURGERY
- 3 CHEMOTHERAPY



Starting the Conversation...
FERTILITY PRESERVATION



FOR MEN DIAGNOSED WITH CANCER

 the
Oncofertility[®]
Consortium
SaveMyFertility.org



2019

21-23 JUNE
SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE

Duncan *et al*, Reproductive
Endocrinology, 8th Edition



Fertility Preservation Options for Women


CLINICAL FERTILITY PRESERVATION OPTIONS

For women, standard methods include:

- 1 PELVIC SHIELDING
- 2 OVARIAN TRANSPOSITION
- 3 EMBRYO BANKING
- 4 EGG BANKING

Experimental methods include:

- 5 GONADAL SUPPRESSION
- 6 OVARIAN TISSUE CRYOPRESERVATION AND TRANSPLANTATION
- 7 IN VITRO MATURATION



CANCER TREATMENT

- 1 RADIATION
- 2 SURGERY
- 3 CHEMOTHERAPY

Starting the Conversation...

FERTILITY PRESERVATION



FOR WOMEN DIAGNOSED WITH CANCER

 the Oncofertility[®] Consortium
SaveMyFertility.org



2019

21-23 JUNE
SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE

Duncan *et al*, Reproductive Endocrinology, 8th Edition



Fertility Preservation Options for Children

- Radiation shielding
- Ovarian transposition
- Ovarian/testicular tissue cryopreservation*

*Investigational



Starting the Conversation...
FERTILITY PRESERVATION

FOR CHILDREN DIAGNOSED WITH CANCER

 the Oncofertility[®]
Consortium
SaveMyFertility.org



2019
21-23 JUNE
SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE



The Fertility Preservation Decision Making Process is Complex



2019
21-23 JUNE
SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE

Challenges of making the decision

- Existential crisis about self, survival, and future
- Decision peripheral to primary diagnosis
- Time constraints
- Overwhelming array of options
- Access to care
- Financial constraints

Challenges of navigating the decision

- Sex
- Age
- Diagnosis
- Treatment type
- Stage of treatment
- Baseline fertility



Duncan *et al*, Reproductive
Endocrinology, 8th Edition



Oncofertility resources for diverse stakeholders

Websites, materials, branding




Oncofertility.northwestern.edu
 Savemyfertility.org
 Preservefertility.northwestern.edu

Conferences, virtual grand rounds, training programs



Patient navigation



Scholarship




Professional networks



A clinical and field-wide infrastructure to support fertility preservation



The National Physicians
Cooperative (**NPC**)
and
Oncofertility Professional
Engagement Network (**OPEN**)



- 117 US Sites
- 231 Sites Globally in 42 Countries
- 19 Pediatric Sites
- Subset perform OTC under IRB-approved protocols



A focus on female fertility preservation – ovarian tissue cryopreservation




Standard ART protocols (i.e. egg and embryo banking) may not apply to those who:

- Are pre-pubertal
- Can not delay cancer treatment
- Can not tolerate hormonal stimulation

Ovarian tissue removal and **cryopreservation** with future use for **transplantation** or additional **emerging technologies**



OTC and tissue transplantation to restore endocrine function and fertility



2019
21-23 JUNE
SAN FRANCISCO


SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE





OTC and tissue transplantation has been successful



Annual Enrollment
>450 total participants



Age Distribution Trends



- **>130 live births worldwide**
 - 26% live birth success rate
- **Hormone production up to 12 years**
 - Average 5 years

Jeruss and Woodruff NEJM, Donnez NEJM 2017
 Pacheco Reprod Sci 2017
 Kim et al J Gynecol Oncol 2016
 Armstrong et al, Future Oncology, 2018
 Smith et al, Future Oncology, 2018



How do we continue to reduce the reproductive health burdens for cancer survivors?

- Make safer (“smart”) cancer treatments
- Determine the fertotoxicity of cancer treatments
- Develop fertoprotective adjuvant therapies
- Engineer new fertility preservation methods



2019

21-23 JUNE


SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE






Making safer or “smart” cancer treatments

- Arsenic trioxide has serious systemic toxicities but is a front line treatment for acute promyelocytic leukemia and has shown promise in adult T-cell leukemia/lymphoma
- This therapeutic hurdle can be lowered by encapsulating drugs into liposome particles (or nanobins)






Nano-encapsulation of arsenic trioxide enhances efficacy against lymphoma in a murine model while minimizing reproductive toxicity



Ahn et al, PLOS One, 2013



Using microphysiologic platforms to screen for the fertoxicity of cancer treatments







2019
 21-23 JUNE
 SAN FRANCISCO
 SUPPORTIVE CARE
 MAKES EXCELLENT
 CANCER CARE POSSIBLE



Xiao et al, Nature Communications, 2017

Identifying the reproductive toxicity of chemotherapeutics

Doxorubicin









2019
 21-23 JUNE
 SAN FRANCISCO
 SUPPORTIVE CARE
 MAKES EXCELLENT
 CANCER CARE POSSIBLE



Xiao et al, Toxicol Sci, 2017

Development of fertoprotective adjuvant therapies

Ovarian pre-treatment with anti-apoptotic agents protects against radiation damage and preserves follicles and fertility






Zelinski *et al*, Fertility Sterility, 2011

Kim *et al*, J Gynecol Oncol, 2016




Engineering new fertility preservation methods

Ovarian tissue transplantation – while successful - may be contraindicated



pancreatic cancer



acute lymphoblastic leukemia

SALL4 / DAPI



2019

21-23 JUNE



SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE




Engineering a 3D printed bioprosthesis ovary



Bioinspired scaffold serves as an ovarian soft tissue transplant



Bioprosthesis, bursa



Multiple generations



2019


21-23 JUNE
SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE



The Future: where we are going

- **No More Cancer**
 - Treatments are changing in real time
- **Full Fertility**
 - Interventional options to preserve fertility
 - Mitigation strategies
- **Fully Accessible**
 - Low/no resource environments
- **Fully Considered by all Stakeholders**
 - Providers, patients, partners, public
- **Eliminate the field**



Acknowledgements

Teresa Woodruff, PhD and Woodruff Lab
Thomas O'Halloran, PhD and O'Halloran Lab
Francesca Duncan, PhD and Duncan Lab
Shuo Xiao, PhD and Xiao Lab
Monica Laronda, PhD and Laronda Lab
So Youn Kim, PhD and Kim Lab
Ramille Shah, PhD and Shah Lab
Lonnie Shea, PhD and Shea Lab
Mary Zelinski, PhD and Zelinski Lab
Oncofertility Consortium Members
National Physicians Cooperative



2019

21-23 JUNE
SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE



Eunice Kennedy Shriver National Institute
of Child Health and Human Development

NIH/NICHD P50HD076188



Join us in Chicago!

2019 Oncofertility Conference

Pediatric Oncofertility: At the Intersection of Oncology, Fertility Preservation, and Patient Care

November 11-13, 2019

Registration Now Open!



Visit www.oncofertility.northwestern.edu for more details

